# MAP3K1

Source: https://onco.cc/targets/map3k1/  
OnCo record `map3k1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MAP3K1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.

## Summary

Component of a protein kinase signal transduction cascade. Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. May phosphorylate the MAPK8/JNK1 kinase.

CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Selumetinib. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes genetic literature 0.38, clinical 0.06, literature 0.97, genetic association 0.61, somatic mutation 0.96, animal model 0.86). IntOGen calls it a driver in 19 cohorts (3 activating, 16 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Adenocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Glioblastoma Multiforme and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: mitogen-activated protein kinase kinase kinase 1; Mitogen-activated protein kinase kinase kinase 1; MAPKKK1; MEKK1
- Tags: cancer-genes-wave
- Symbol: MAP3K1
- Class: kinase
- Biology: Component of a protein kinase signal transduction cascade. Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. May phosphorylate the MAPK8/JNK1 kinase. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway. Locus 5q11.2 (HGNC).
- Where found: Breast cancer: Open Targets association 0.77 with breast cancer (MONDO_0007254); IntOGen driver in 8 cohorts (BRCA); Ovarian cancer: Open Targets association 0.64 with ovarian cancer (MONDO_0008170); Endometrial cancer: Open Targets association 0.56 with endometrial cancer (MONDO_0011962); IntOGen driver in 2 cohorts (UCEC); Renal cell carcinoma: IntOGen driver in 2 cohorts (CCRCC); Colorectal cancer: IntOGen driver in 2 cohorts (COAD, COADREAD); Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.06; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 16 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6848: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6848
- UniProt Q13233: https://www.uniprot.org/uniprotkb/Q13233/entry
- NCBI Gene 4214: https://www.ncbi.nlm.nih.gov/gene/4214
- Ensembl ENSG00000095015: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000095015

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/map3k1.json